AI Article Synopsis
- * A study analyzed HZ hospitalisations in Spain from 1998 to 2018, revealing 65,401 cases and a higher hospitalisation rate among males and individuals over 65, with leukaemia and solid tumors increasing risks of readmission and mortality.
- * The findings support prioritizing vaccination for high-risk groups outlined by Spanish health authorities and establish a baseline for evaluating vaccination policies in the future.
Article Abstract
BackgroundHerpes zoster (HZ) affects 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age and the presence of immunocompromising conditions. In Spain, vaccination guidelines were recently updated to include the recommendation of the new recombinant zoster vaccine (RZV) for certain risk groups.AimTo describe the epidemiology of HZ-related hospitalisations in Spain in order to prioritise vaccination recommendations and define a baseline to monitor the effectiveness of vaccination policies.MethodsRetrospective study using the National Health System's Hospital Discharge Records Database, including all HZ-related hospitalisations from 1998 to 2018.ResultsThe 65,401 HZ-related hospitalisations, corresponded to an annual mean hospitalisation rate of 6.75 per 100,000 population. There was an increasing trend of HZ hospitalisations over the study period. This rate was higher in males and older age groups, particularly over 65 years. Comorbidities with higher risk of readmission were leukaemia/lymphoma (RR 2.4; 95% CI: 2.3-2.6) and solid malignant neoplasm (RR 2.2; 95% CI: 2.1-2.4). Comorbidities associated with higher risk of mortality were leukaemia/lymphoma (RR 2.9; 95% CI: 2.7-3.2), solid malignant neoplasm (RR 2.9; 95% CI: 2.7-3.1) and HIV infection (RR 2.2; 95% CI: 1.8-2.7).ConclusionOf all patients hospitalised with HZ, those with greater risk of mortality or readmission belonged to the groups prioritised by the current vaccination recommendations of the Spanish Ministry of Health. Our study provided relevant information on clinical aspects of HZ and established the base for future assessments of vaccination policies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951257 | PMC |
| http://dx.doi.org/10.2807/1560-7917.ES.2023.28.8.2200390 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Ultrasound-Guided Transverse Abdominal Plane Block for Residual Pain After Pulsed Radiofrequency in Abdominal Acute/Subacute Herpes Zoster-Related Pain.
J Ultrasound Med
December 2024
Department of Pain Management, Wuhan No. 1 Hospital, Wuhan, China.
Article Synopsis
- Pulse radiofrequency (PRF) combined with transverse abdominal plane (TAP) block was studied to improve pain relief in patients suffering from herpes zoster (HZ), as some patients still experience pain despite PRF treatment.
- The study involved 137 HZ patients divided into two groups: one receiving TAP block and the other receiving normal saline, with pain and quality of life assessed at multiple follow-up points.
- Results indicated the TAP group experienced significantly less pain, improved sleep quality, and a better quality of life compared to the normal saline group at various follow-up intervals, alongside a reduction in the use of pain medications.
8. Herpes zoster and post herpetic neuralgia.
Pain Pract
October 2024
Pain Clinic, Department of Anesthesiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Article Synopsis
- Patients with postherpetic neuralgia (PHN) experience persistent pain following a herpes zoster infection, with a significant portion of those affected suffering from a reduced quality of life and challenging treatment options.
- The review highlights the effectiveness of antiviral therapy within 72 hours of symptom onset as crucial for managing acute herpes zoster pain, alongside analgesics and various medications.
- For patients who do not respond to conventional treatments, newer interventional techniques, particularly pulsed radiofrequency treatment of the dorsal root ganglion, show promise in alleviating pain associated with PHN.
Efficacy of Gasserian Ganglion High-Voltage, Long-Duration Pulsed Radiofrequency Combined With Block on Acute/Subacute Zoster-Related Trigeminal Neuralgia.
Pain Res Manag
September 2024
Department of Emergency Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China.
Article Synopsis
- Trigeminal postherpetic neuralgia (TPHN) is a chronic pain condition resulting from herpes zoster that has significant socioeconomic impacts, prompting the need for effective treatment options.
- A study involving 83 patients used high-voltage, long-duration pulsed radiofrequency (HL-PRF) on the Gasserian ganglion and showed significant pain reduction, with lower Numerical Rating Scale (NRS) scores in the acute herpes phase compared to the subacute phase.
- The overall effectiveness of this treatment was 74.7%, with a lower incidence of TPHN in the acute group (12.77%) versus the subacute group (33.33%), and no serious adverse reactions were reported.
Assessment of ultrasound-guided intercostal nerve block for acute herpes zoster and its' possible prophylaxis for postherpetic neuralgia: a retrospective and case-controlled trial.
Korean J Pain
October 2024
Department of Anesthesiology, Beijing Chuiyangliu Hosptial Affiliated to Tsinghua University, Beijing, China.
Article Synopsis
- - The study compared two treatment methods, intercostal nerve block (ICNB) and thoracic paravertebral block (TPVB), for managing pain from herpes zoster and preventing long-term pain (post-herpetic neuralgia) in 128 patients.
- - Results showed that both treatment methods significantly reduced the burden of illness compared to standard antiviral treatment alone, with no notable difference in effectiveness between TPVB and ICNB.
- - ICNB was quicker to perform than TPVB and both methods were effective, suggesting ICNB as a practical alternative for managing herpes zoster pain with fewer side effects.
Assessment of the humoral immune status of varicella-zoster virus in patients with diffuse connective tissue diseases.
Front Med (Lausanne)
September 2024
Department of Rheumatology and Immunology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China.
Background: Diffuse connective tissue diseases (DCTDs) require long-term immunosuppressive treatment, increasing the risk of varicella-zoster virus (VZV) infection. This study aims to evaluate the humoral immune status against VZV in DCTD patients and explore factors that may influence their immune levels.
Methods: This is a retrospective cohort study that collected data from adult DCTD patients (≥18 years) attending our outpatient clinic.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!